Despite of this bias, most of our patients showed an initial drop of PSA levels at the first follow-up, indicating that PSMA-PET/CT-based MDT in oligometastatic prostate cancer is able to temporarily reduce the main tumor burden in the majority of patients. This evidence concerns the gene FOLH1 and prostate cancer.